Snapshot from Aug 25, 2026 at 07:00 UTC. For live data and tracking: View Live
Events / Business / Hanmi Pharm Genentech Obesity Licensing Deal
Business licensing agreement

Hanmi Pharm Genentech Obesity Licensing Deal

Analysis based on 9 articles · First reported Jul 20, 2026 · Last updated Aug 24, 2026

Sentiment
70
Attention
4
Articles
9
Market Impact
General
Live prominence charts, article sentiment distribution, and event development timeline available on the Ergen Dashboard
Market Impact

The deal is expected to positively impact Hanmi Pharm's stock price and financial position, providing significant upfront capital and potential future royalties. For Roche and F. Hoffmann-La Roche — Genentech, the licensing strengthens their cardiometabolic pipeline, potentially enhancing their competitive position in the obesity treatment market.

Pharmaceuticals Biotechnology
Event Summary

On August 24, 2026, Hanmi Pharm announced an exclusive licensing agreement with F. Hoffmann-La Roche — Genentech, a member of the Roche Group, for the worldwide development, manufacturing, and commercialization of HM17321, a novel UCN2 analog for obesity and associated conditions, excluding South Korea. The deal includes an upfront payment of USD 190 million, potential milestone payments, and tiered royalties, with a total value up to USD 2.3 billion. HM17321 is a first-in-class non-incretin therapy designed to promote weight loss while preserving lean body mass, potentially addressing limitations of existing GLP-1 therapies. Hanmi will complete Phase 1 clinical trials, after which F. Hoffmann-La Roche — Genentech will lead Phase 2 and beyond. The agreement highlights the growing focus on differentiated obesity treatments and the value of Hanmi's R&D pipeline.

Key Actions
100 Hanmi Pharm signed licensing agreement F. Hoffmann-La Roche — Genentech
80 F. Hoffmann-La Roche — Genentech paid upfront Hanmi Pharm
Entities Involved
stock
Hanmi Pharm
Hanmi is the licensor, receiving USD 190 million upfront and up to USD 2.3 billion in total deal value. This validates its R&D capabilities and provides substantial financial upside.
Importance 100.0 Sentiment 90.0
subs
F. Hoffmann-La Roche — Genentech
F. Hoffmann-La Roche — Genentech gains exclusive rights to a promising obesity therapy, expanding its pipeline. The deal involves significant financial commitment but offers potential long-term returns.
Importance 90.0 Sentiment 70.0
stock
Roche
As the parent of F. Hoffmann-La Roche — Genentech, Roche strengthens its cardiometabolic portfolio, aligning with its strategy to address obesity and related conditions.
Importance 80.0 Sentiment 70.0
govactor
United States — Food and Drug Administration
The FDA granted IND clearance for HM17321 in November 2025, enabling the Phase 1 trial. Its regulatory role is crucial for the drug's development.
Importance 30.0 Sentiment 0.0
cnt
South Korea
South Korea is the home country of Hanmi and is excluded from the licensing territory, but the deal highlights the country's growing biotech sector.
Importance 20.0 Sentiment 0.0
curr
United States — United States dollar
The deal is denominated in USD, with payments of USD 190 million upfront and up to USD 2.3 billion total, reflecting the financial scale of the agreement.
Importance 10.0 Sentiment 0.0
per
Choi In-young
As Hanmi's Head of R&D, Choi is a spokesperson for the deal, emphasizing the scientific value of HM17321.
Importance 10.0 Sentiment 0.0
per
Boris L. Zaitra
As Roche's head of Corporate Business Development, Zaïtra is a spokesperson for the deal, highlighting its strategic importance.
Importance 10.0 Sentiment 0.0
Relationships
F. Hoffmann-La Roche — Genentech related ↔ Roche
Roche related ↔ United States — Food and Drug Administration
ERGEN INTELLIGENCE
Track this event live

Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.

Open Dashboard

About Ergen

Ergen is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.ergen.ai.